advanced search

INJECTION

OPPORTUNITIES FOR INNOVATION WITH BIOSIMILARS
PREFILLED SYRINGES
Dr Iain Simpson
Phillips-Medisize
OPPORTUNITIES FOR INNOVATION WITH BIOSIMILARS
Iain Simpson and George Spooner investigate the use of drug delivery systems that support self-administration of biologic drugs, and specifically biosimilars, for the treatment of chronic diseases. This article is based on research conducted by both authors as part of the MPhil in Therapeutic Sciences at the University of Cambridge (UK) and supported by Phillips-Medisize.
Pro-Tects – A NOVEL SOLUTION TO THE CHALLENGE OF BIOLOGIC INSTABILITY
INJECTION
Dr Shane Smith
Glycome BioPharma
Pro-Tects – A NOVEL SOLUTION TO THE CHALLENGE OF BIOLOGIC INSTABILITY
Shane Smith, Eoin Scanlan and Paula Colavita discusses the difficulty inherent in developing parenteral biologic products due to the challenge of creating a stable formulation in the face of surface-mediated protein aggregation and introduces Pro-Tects – Glycome’s patented surface-treatment technology platform that offers a solution to this critical issue without introducing further development challenges.
ENABLING LARGE-VOLUME, HIGH-DOSE SUBCUTANEOUS AUTOINJECTIONS WITH CARTRIDGE-BASED TECHNOLOGIES
INJECTION
Michael McGowan
SHL Medical
ENABLING LARGE-VOLUME, HIGH-DOSE SUBCUTANEOUS AUTOINJECTIONS WITH CARTRIDGE-BASED TECHNOLOGIES
Michael McGowan, examines the emerging interest in autoinjectors that are capable of delivering higher injection volumes into the subcutaneous space and considers the potential benefits of SHL Medical’s cartridge-based 3 and 5 mL Maggie® autoinjectors.
ENABLING DRUG DEVELOPMENT THROUGH DRUG DELIVERY MANUFACTURING
WEARABLES
Dr Andrei Yosef
Eitan Medical
ENABLING DRUG DEVELOPMENT THROUGH DRUG DELIVERY MANUFACTURING
Andrei Yosef looks at the role of manufacturing in the development of drug delivery devices and highlights the benefits of the company’s Sorrel device, which enables pharma companies to experiment during clinical trials to ensure that drugs produced are safe and cost-effective.
PRODUCT SHOWCASE: New Requirements for Injection Devices Make Advanced Testing Solutions Necessary
INDUSTRIALISATION
Peter Schmidt
ZwickRoell
PRODUCT SHOWCASE: New Requirements for Injection Devices Make Advanced Testing Solutions Necessary
ZwickRoell showcases its advanced testing solutions for injection devices including pens, autoinjectors and on-body delivery systems.
OXYCAPT: SUPERIOR PRIMARY CONTAINERS FOR BIOLOGICS AND GENE AND CELL THERAPIES
PREFILLED SYRINGES
Yasuaki Yoshimura
Mitsubishi Gas Chemical
OXYCAPT: SUPERIOR PRIMARY CONTAINERS FOR BIOLOGICS AND GENE AND CELL THERAPIES
Yasuaki Yoshimura and Tomohiro Suzuki review the advantages that OXYCAPT, the company’s multilayer material for vials, offers to biologics and gene and cell therapies, and discuss the results of recent tests into low temperature storage and dimethyl sulfoxide resistance.
Interview: Kymanox Executive Advisors Mathias Romacker, Fran DeGrazio & Paul Jansen
INTERVIEW
Guy Furness
Kymanox
Interview: Kymanox Executive Advisors Mathias Romacker, Fran DeGrazio & Paul Jansen
Mathias Romacker, Fran DeGrazio and Paul Jansen sit down with Guy Furness, to discuss what it is that has driven Kymanox’s rapid rise in the drug delivery space and what makes the consulting company’s model so successful, as well as to share their expertise on a variety of topics in an illuminating discussion, including connectivity, how large and small drug developers engage with consultancies, 5 mL autoinjectors and the interface between drug primary packaging and delivery devices.
SILICONE-OIL-FREE PREFILLED SYRINGE SYSTEMS – GUIDANCE FOR SELECTING THE APPROPRIATE PACKAGING MATERIALS AND FOR SILICONISATION
PREFILLED SYRINGES
Bernd Zeiss
Gerresheimer
SILICONE-OIL-FREE PREFILLED SYRINGE SYSTEMS – GUIDANCE FOR SELECTING THE APPROPRIATE PACKAGING MATERIALS AND FOR SILICONISATION
Bernd Zeiss addresses the influence of silicone oil on syringe systems and highlights the advantages and possibilities of novel silicone-oil-free prefillable syringes, both for glass and for plastic syringes.
Interview: Gabriel Zenker, Aptar Pharma
INTERVIEW
Guy Furness
Aptar Pharma
Interview: Gabriel Zenker, Aptar Pharma
Gabriel Zenker talks with ONdrugDelivery about Aptar Pharma’s ambitions for the parenterals sector. Mr Zenker explains how Aptar, already a major player in the pulmonary, nasal, ophthalmic and dermal markets, is undertaking a major expansion of its facilities, boosting the company’s capacity, capabilities and technologies, to provide its extensive service and product offering to the exciting injectables space.
ACCELERATING NOVEL THERAPIES TO THE CLINIC – CUSTOM SOLUTIONS
PREFILLED SYRINGES
Asmita Khanolkar
SMC Ltd
ACCELERATING NOVEL THERAPIES TO THE CLINIC – CUSTOM SOLUTIONS
Asmita Khanolkar discusses the key offerings necessary to accelerate “speed to clinic” for custom manufacturing solutions.
THE OPERATIONS PERSPECTIVE: BEST PRACTICES FROM 70 YEARS IN INJECTION DEVICE MANUFACTURING
INJECTION
John Swift
Owen Mumford
THE OPERATIONS PERSPECTIVE: BEST PRACTICES FROM 70 YEARS IN INJECTION DEVICE MANUFACTURING
John Swift looks at how the company has evolved over 70 years, introduces its latest disposable autoinjector, Aidaptus, and considers how it plans to actively reduce risk in its supply chain.
LOW-COMPLEXITY, EASY-TO-USE WEARABLE INJECTION PLATFORM
WEARABLES
Jesper Roested
LOW-COMPLEXITY, EASY-TO-USE WEARABLE INJECTION PLATFORM
Jesper Roested discusses the increasing prevalence of biologics formulated for large-volume injections in drug development and how wearable devices, including Subcuject’s offering, may be a better solution for delivering these drugs than scaled-up conventional autoinjectors.
REDUCE PHARMA DEVELOPMENT TIME: LARGE-VOLUME SUBCUTANEOUS DELIVERY WITH THE ENFUSE<sup>®</sup>
WEARABLES
Dr Mehul Desai
Enable Injections
REDUCE PHARMA DEVELOPMENT TIME: LARGE-VOLUME SUBCUTANEOUS DELIVERY WITH THE ENFUSE®
Mehul Desai discusses how Enable Injections' enFuse® delivery system provides a flexible alternative for subcutaneous administration of high-volume therapeutics.
ANTICIPATING & MITIGATING CHALLENGES IN THE COMMERCIALISATION OF PREFILLED SYRINGES & INJECTION DEVICES – A TECHNICAL DRUG PRODUCT PERSPECTIVE
PREFILLED SYRINGES
Dr Andrea Allmendinger
ten23 health
ANTICIPATING & MITIGATING CHALLENGES IN THE COMMERCIALISATION OF PREFILLED SYRINGES & INJECTION DEVICES – A TECHNICAL DRUG PRODUCT PERSPECTIVE
Andrea Allmendinger and Hanns-Christian Mahler both at ten23 health, provide an insight into the challenges of integrated development of drug product and device design and fill-finish manufacturing operations.
A TALE OF TWO SPRINGS
PREFILLED SYRINGES
Sebastian Block
Scherdel Medtec North America
A TALE OF TWO SPRINGS
Sebastian Block and Drew Jelgerhuis introduce two types of springs and highlight their important role in drug delivery devices.
ENGINEERING ADVANCES IN NEEDLE GEOMETRY TO ACCOMMODATE VISCOUS BIOLOGICS
INJECTION
Silvia Gallina
Stevanato Group
ENGINEERING ADVANCES IN NEEDLE GEOMETRY TO ACCOMMODATE VISCOUS BIOLOGICS
Silvia Gallina discusses the challenges faced in administering highly viscous biologics to patients via subcutaneous injection, and how Stevanato Group’s new special thin-wall needles are able to tackle them.
BEING PREPARED FOR PHARMA INNOVATION IS KEY IN 2023
INJECTION
Victoria Morgan
West Pharmaceutical Services
BEING PREPARED FOR PHARMA INNOVATION IS KEY IN 2023
Victoria Morgan and Ana Marques Kuschel discuss three recent innovations that West Pharmaceutical Services has introduced to enable its partners to respond to specific market-driven challenges, from pandemic-driven pressures on fill-finish productivity to the underlying shift towards biologics and the accelerated growth of home-based treatment.
EXTRACTABLES/LEACHABLES TESTING CONSIDERATIONS FOR SINGLE-USE SYSTEMS
EXPERT VIEW
Sandi Schaible
EXTRACTABLES/LEACHABLES TESTING CONSIDERATIONS FOR SINGLE-USE SYSTEMS
Sandi Schaible discusses testing considerations for extractables and leachables along with the regulatory environment for single-use systems.
Pharmapack Expert Panel on Patient-Centric Digital Health: Interview with Ben Cox, Team Consulting
INTERVIEW
Dr Ben Cox
Team Consulting
Pharmapack Expert Panel on Patient-Centric Digital Health: Interview with Ben Cox, Team Consulting
With Pharmapack returning to its traditional February timing in 2023, Team Consulting will be chairing a Day 1 expert panel discussion on patient-centric digital health solutions. Interviewed here, Ben Cox provides insight into trends the panel will discuss, lays out the current status of the industry with respect to digital health and considers what to look forward to at Pharmapack this year.
DESIGNING EFFECTIVE AND ENGAGING DIGITAL SOLUTIONS TO DRIVE ADHERENCE
CONNECTIVITY
Florian Krummenacher
Ypsomed
DESIGNING EFFECTIVE AND ENGAGING DIGITAL SOLUTIONS TO DRIVE ADHERENCE
Florian Krummenacher and Philippe Müller discuss the effectiveness of combining connected injection devices with digital solutions to drive therapy outcomes.
PATIENT JOURNEY AS THE FOUNDATION FOR HOLISTIC CONNECTED DEVICE DEVELOPMENT
CONNECTIVITY
Mark Tunkel
Nemera
PATIENT JOURNEY AS THE FOUNDATION FOR HOLISTIC CONNECTED DEVICE DEVELOPMENT
Mark Tunkel and Cécile Gross consider the development of connected drug delivery devices and identify how understanding the patient journey from diagnosis to treatment can be used as an early-stage decision-making tool.
Connected Drug Delivery – Is the Near-Term Opportunity in Clinical Development? – an Interview with Oliver Eden
INTERVIEW
Dr Oliver Eden
Jabil Healthcare
Connected Drug Delivery – Is the Near-Term Opportunity in Clinical Development? – an Interview with Oliver Eden
Oliver Eden of Jabil Healthcare looks at the factors influencing the return on investment metrics in clinical development and introduces Jabil’s autoinjector platform Qfinity™ and its connected version, Qfinity+™.
DIGITAL HEALTH: ADDRESSING MODERN HEALTHCARE CHALLENGES WITH SENSORS
CONNECTIVITY
Dr Haykel Ben Jamaa
Sensirion
DIGITAL HEALTH: ADDRESSING MODERN HEALTHCARE CHALLENGES WITH SENSORS
Haykel Ben Jamaa explores why modern society needs digital health and how it is organised and implemented, with a focus on sensing technologies empowering digital health technologies.
AREAS TO WATCH IN CONNECTED DRUG DELIVERY DEVICE DEVELOPMENT
CONNECTIVITY
Michael Earl
Owen Mumford
AREAS TO WATCH IN CONNECTED DRUG DELIVERY DEVICE DEVELOPMENT
Michael Earl identifies areas of development in the field of connected drug delivery devices, providing an insight into what can be expected in the coming years. He draws on Owen Mumford’s own research, as well as discussions with industry experts and counterparts.
Top